AstraZeneca announced a landmark $50 billion investment plan in the US by 2030, a strategic move aimed at reinforcing America’s global leadership in pharmaceutical manufacturing and R&D. This significant commitment is projected to create tens of thousands of new, highly skilled direct and indirect jobs nationwide, fueling economic growth while accelerating the delivery of next-generation medicines to patients in the U.S. and globally.
The highlight of this investment is a new, multi-billion-dollar drug substance manufacturing facility in the Commonwealth of Virginia, slated to become AstraZeneca’s largest single manufacturing investment globally.
This center will utilize AI, automation, and data analytics to produce active pharmaceutical ingredients for the company’s weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and various combination small-molecule products. This capital influx also builds upon a previous $3.5 billion U.S. investment announced in November 2024.
The $50 billion investment over the next five years will also span across AstraZeneca’s extensive U.S. R&D and manufacturing footprint, featuring:
— Expansion of its R&D facility in Gaithersburg, Maryland.
— An R&D center in Kendall Square, Cambridge, Massachusetts.
— Manufacturing facilities for cell therapy in Rockville, Maryland, and Tarzana, California.
— Continuous manufacturing expansion in Mount Vernon, Indiana.
— Specialty manufacturing expansion in Coppell, Texas.
— New sites focused on supplying clinical trials.
— Continued growing R&D investment in novel medicines.
These collective investments are pivotal to AstraZeneca’s ambition of achieving $80 billion in total revenue by 2030, with a strategic goal for the U.S. to generate 50% of that revenue.
KEY QUOTES:
“For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation’s new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.”
Howard Lutnick, US Secretary of Commerce
“I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation’s domestic supply chain. Advanced manufacturing is at the heart of Virginia’s dynamic economy, so I am thrilled that AstraZeneca, one of the world’s leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.”
Governor Glenn Youngkin, Commonwealth of Virginia
“Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines.”
Pascal Soriot, Chief Executive Officer, AstraZeneca
